Percutaneous Coronary Intervention in Patients with Diabetes: Current Concepts and Future Directions

Overview

Journal J Diabetes Sci Technol

Specialty Endocrinology

Date 2014 May 31

PMID 24876623

Citations 16

Authors

Ehrin J Armstrong

Johannes Waltenberger

Jason H Rogers

Affiliations

Soon will be listed here.

Abstract

Patients with diabetes and coronary artery disease represent a challenging and growing subset of the population. Although surgical revascularization is the preferred treatment for patients with diabetes and multivessel coronary artery disease with stable angina, a significant proportion of diabetic patients undergo percutaneous revascularization due to comorbidities, presence of single-vessel disease, or presentation with myocardial infarction. The development of drug-eluting stents has significantly improved the results of percutaneous revascularization among diabetic patients, but a number of challenges remain, including higher rates of restenosis and stent thrombosis among diabetic patients. With current technologies, the outcomes of diabetic patients treated with noninsulin agents have approached that of nondiabetic patients. In comparison, patients with diabetes who require insulin therapy represent a high-risk cohort with increased rates of target vessel failure after coronary revascularization. The development of bioresorbable stents and new drug elution systems may provide additional future benefit among patients with diabetes undergoing percutaneous coronary artery revascularization.

Citing Articles

90-day mortality risk related to postoperative potassium levels in patients undergoing coronary bypass surgery.

Kjeldgaard M, Maeng M, Torp-Pedersen C, Sogaard P, Kragholm K, Andreasen J J Mol Cell Cardiol Plus. 2025; 4():100035.

PMID: 39801695 PMC: 11708319. DOI: 10.1016/j.jmccpl.2023.100035.

Safety and Efficacy of the Supreme Biodegradable Polymer Sirolimus-Eluting Stent in Patients With Diabetes Mellitus.

Thomas A, Kereiakes D, Baumbach A, Windecker S, Pietras C, Dressler O J Soc Cardiovasc Angiogr Interv. 2024; 1(2):100033.

PMID: 39132558 PMC: 11307809. DOI: 10.1016/j.jscai.2022.100033.

Patients With Diabetes at High Bleeding Risk With 1-Month Dual Antiplatelet Therapy: Onyx ONE Clear Results.

Kedhi E, Windecker S, Latib A, Kirtane A, Kandzari D, Mehran R J Soc Cardiovasc Angiogr Interv. 2024; 1(5):100441.

PMID: 39131461 PMC: 11307822. DOI: 10.1016/j.jscai.2022.100441.

Fractional flow reserve measurements and long-term mortality-results from the FLORIDA study.

Boeckling F, Stahli B, Rudolph T, Lutz M, Schatz A, Vogelmann T Front Cardiovasc Med. 2024; 11:1337941.

PMID: 38404721 PMC: 10885355. DOI: 10.3389/fcvm.2024.1337941.

Spatial Reorganization of Liquid Crystalline Domains of Red Blood Cells in Type 2 Diabetic Patients with Peripheral Artery Disease.

Bianchetti G, Rizzo G, Serantoni C, Abeltino A, Rizzi A, Tartaglione L Int J Mol Sci. 2022; 23(19).

PMID: 36232429 PMC: 9570208. DOI: 10.3390/ijms231911126.

References

Kereiakes D, Cutlip D, Applegate R, Wang J, Yaqub M, Sood P . Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: results from the SPIRIT IV clinical trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System). J Am Coll Cardiol. 2010; 56(25):2084-9. DOI: 10.1016/j.jacc.2010.10.006. View

Kolandaivelu K, Swaminathan R, Gibson W, Kolachalama V, Nguyen-Ehrenreich K, Giddings V . Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation. 2011; 123(13):1400-9. PMC: 3131199. DOI: 10.1161/CIRCULATIONAHA.110.003210. View

Garg P, Normand S, Silbaugh T, Wolf R, Zelevinsky K, Lovett A . Drug-eluting or bare-metal stenting in patients with diabetes mellitus: results from the Massachusetts Data Analysis Center Registry. Circulation. 2008; 118(22):2277-85, 7p following 2285. DOI: 10.1161/CIRCULATIONAHA.108.820159. View

Garg S, Bourantas C, Serruys P . New concepts in the design of drug-eluting coronary stents. Nat Rev Cardiol. 2013; 10(5):248-60. DOI: 10.1038/nrcardio.2013.13. View

Mazeika P, Prasad N, Bui S, Seidelin P . Predictors of angiographic restenosis after coronary intervention in patients with diabetes mellitus. Am Heart J. 2003; 145(6):1013-21. DOI: 10.1016/S0002-8703(03)00085-1. View

Sinning J, Baumgart D, Werner N, Klauss V, Baer F, Hartmann F . Five-year results of the Multicenter Randomized Controlled Open-Label Study of the CYPHER Sirolimus-Eluting Stent in the Treatment of Diabetic Patients with De Novo Native Coronary Artery Lesions (SCORPIUS) study: a German multicenter investigation.... Am Heart J. 2012; 163(3):446-53, 453.e1. DOI: 10.1016/j.ahj.2011.12.010. View

Diletti R, Serruys P, Farooq V, Sudhir K, Dorange C, Miquel-Hebert K . ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the.... Am Heart J. 2012; 164(5):654-63. DOI: 10.1016/j.ahj.2012.08.010. View

Bangalore S, Kumar S, Fusaro M, Amoroso N, Kirtane A, Byrne R . Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22,844 patient years of follow-up from randomised trials. BMJ. 2012; 345:e5170. PMC: 3415955. DOI: 10.1136/bmj.e5170. View

Kooy A, de Jager J, Lehert P, Bets D, Wulffele M, Donker A . Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med. 2009; 169(6):616-25. DOI: 10.1001/archinternmed.2009.20. View

10.

Wild S, Roglic G, Green A, Sicree R, King H . Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004; 27(5):1047-53. DOI: 10.2337/diacare.27.5.1047. View

11.

Silber S, Serruys P, Leon M, Meredith I, Windecker S, Neumann F . Clinical outcome of patients with and without diabetes mellitus after percutaneous coronary intervention with the resolute zotarolimus-eluting stent: 2-year results from the prospectively pooled analysis of the international global RESOLUTE program. JACC Cardiovasc Interv. 2013; 6(4):357-68. DOI: 10.1016/j.jcin.2012.11.006. View

12.

Nathan D, Cleary P, Backlund J, Genuth S, Lachin J, Orchard T . Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005; 353(25):2643-53. PMC: 2637991. DOI: 10.1056/NEJMoa052187. View

13.

Dagenais G, Lu J, Faxon D, Kent K, Lago R, Lezama C . Effects of optimal medical treatment with or without coronary revascularization on angina and subsequent revascularizations in patients with type 2 diabetes mellitus and stable ischemic heart disease. Circulation. 2011; 123(14):1492-500. DOI: 10.1161/CIRCULATIONAHA.110.978247. View

14.

Hermiller J, Raizner A, Cannon L, Gurbel P, Kutcher M, Wong S . Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial. J Am Coll Cardiol. 2005; 45(8):1172-9. DOI: 10.1016/j.jacc.2004.10.075. View

15.

Mosseri M, Nahir M, Rozenman Y, Lotan C, Admon D, Raz I . Diffuse narrowing of coronary arteries in diabetic patients: the earliest phase of coronary artery disease. Cardiology. 1998; 89(2):103-10. DOI: 10.1159/000006764. View

16.

Timmer J, Ottervanger J, de Boer M, Boersma E, Grines C, Westerhout C . Primary percutaneous coronary intervention compared with fibrinolysis for myocardial infarction in diabetes mellitus: results from the Primary Coronary Angioplasty vs Thrombolysis-2 trial. Arch Intern Med. 2007; 167(13):1353-9. DOI: 10.1001/archinte.167.13.1353. View

17.

von Birgelen C, Basalus M, Tandjung K, van Houwelingen K, Stoel M, Louwerenburg J . A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial. J Am Coll Cardiol. 2012; 59(15):1350-61. DOI: 10.1016/j.jacc.2012.01.008. View

18.

Aronson D, Edelman E . Revascularization for coronary artery disease in diabetes mellitus: angioplasty, stents and coronary artery bypass grafting. Rev Endocr Metab Disord. 2010; 11(1):75-86. PMC: 3076727. DOI: 10.1007/s11154-010-9135-3. View

19.

Farkouh M, Domanski M, Sleeper L, Siami F, Dangas G, Mack M . Strategies for multivessel revascularization in patients with diabetes. N Engl J Med. 2012; 367(25):2375-84. DOI: 10.1056/NEJMoa1211585. View

20.

Wallentin L, Becker R, Budaj A, Cannon C, Emanuelsson H, Held C . Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361(11):1045-57. DOI: 10.1056/NEJMoa0904327. View